Linden H - Search Results

1

Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.

Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Eubank WB, et al. Among authors: linden h. AJR Am J Roentgenol. 2004 Aug;183(2):479-86. doi: 10.2214/ajr.183.2.1830479. AJR Am J Roentgenol. 2004. PMID: 15269044

2

Myalgias and arthralgias associated with paclitaxel.

Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, West HL. Garrison JA, et al. Oncology (Williston Park). 2003 Feb;17(2):271-7; discussion 281-2, 286-8. Oncology (Williston Park). 2003. PMID: 12632867 Free article. Review.

3

Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB. Mankoff DA, et al. J Nucl Med. 2003 Nov;44(11):1806-14. J Nucl Med. 2003. PMID: 14602864 Free article.

4

Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations.

Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Agoff SN, et al. Among authors: linden h. Am J Clin Pathol. 2003 Nov;120(5):725-31. doi: 10.1309/42F0-0D0D-JD0J-5EDT. Am J Clin Pathol. 2003. PMID: 14608899

5

Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA. Dunnwald LK, et al. Cancer. 2005 Feb 15;103(4):680-8. doi: 10.1002/cncr.20831. Cancer. 2005. PMID: 15637688 Free article.

6

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Linden HM, et al. J Clin Oncol. 2006 Jun 20;24(18):2793-9. doi: 10.1200/JCO.2005.04.3810. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682724

7

Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?

Linden HM, Krohn KA, Livingston RB, Mankoff DA. Linden HM, et al. Clin Cancer Res. 2006 Oct 1;12(19):5608-10. doi: 10.1158/1078-0432.CCR-06-1152. Clin Cancer Res. 2006. PMID: 17020961 No abstract available.

8

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Specht JM, et al. Breast Cancer Res Treat. 2007 Sep;105(1):87-94. doi: 10.1007/s10549-006-9435-1. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268819

9

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Linden HM, et al. J Clin Oncol. 2007 Feb 20;25(6):656-61. doi: 10.1200/JCO.2006.07.0847. J Clin Oncol. 2007. PMID: 17308269 Clinical Trial.

10

18F-Fluoroestradiol.

Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. Sundararajan L, et al. Semin Nucl Med. 2007 Nov;37(6):470-6. doi: 10.1053/j.semnuclmed.2007.08.003. Semin Nucl Med. 2007. PMID: 17920354 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

336 results

Search Page